WALTHAM, Mass., March 5, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the following investor conferences during the month of March: Cowen and Company 39th Annual Health Care Conference Monday, March 11, 2019 at 1:30 p.m. ET Location: Boston, MA Barclays Global Healthcare Conference Wednesday, March 13, 2019 at 2:35… More

AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference WALTHAM, Mass., February 19, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted Myles, chief financial officer and Julie Krop, MD, chief medical officer will participate in a fireside chat at 10:00 a.m…. More

Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM, Mass., (February 7, 2019) – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2018, which were in-line with previously announced… More

Adds Next Generation Small Molecule Anticoagulant Reversal Agent to Development Pipeline to Leverage AMAG’s Expertise in Hematology WALTHAM, Mass. January 17, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG adds ciraparantag to its development portfolio…. More

WALTHAM, Mass., Jan. 15, 2019 — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Christine Moulton Clemson, Ph.D., M.S.C.I., as vice president, medical affairs, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Clemson will serve as a medical lead for AMAG’s women’s healthcare products. “Christine brings broad medical affairs, scientific, and functional leadership experience that will greatly contribute to our… More

Achieves 2018 revenue of between $471 million and $476 million, including approximately 28% growth in Feraheme® (ferumoxytol injection) sales Acquisition of two development-stage assets creates a strong and diversified portfolio, leveraging therapeutic area expertise[1] WALTHAM, Mass., January 7, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced preliminary unaudited fourth quarter and full year 2018… More

Next Generation Anticoagulant Reversal Agent, Ciraparantag, Will Add Innovative Clinical Stage Asset to AMAG’s Hematology Portfolio  Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass. December 13, 2018 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG… More

WALTHAM, Mass. December 3, 2018 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that research supported by the Company, “Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients Following a Single Course of Ferumoxytol: Results of a 6-Month Extension Study,” was presented as a poster presentation on Saturday, December 1, 2018, at… More

WALTHAM, Mass., November 29, 2018 – As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has awarded four grants totaling nearly $300,000 to independent researchers in the maternal health field. “AMAG is committed to advancing research… More

WALTHAM, Mass., November 6, 2018 — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate in the following investor conferences: • Jefferies London Healthcare Conference Thursday, November 15, 2018 at 8:00 a.m. GMT (3:00 a.m. ET) Location: London, U.K. • Piper Jaffray Healthcare Conference Tuesday, November 27, 2018 at 8:00 a.m. ET… More